JP2018515618A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515618A5 JP2018515618A5 JP2018511527A JP2018511527A JP2018515618A5 JP 2018515618 A5 JP2018515618 A5 JP 2018515618A5 JP 2018511527 A JP2018511527 A JP 2018511527A JP 2018511527 A JP2018511527 A JP 2018511527A JP 2018515618 A5 JP2018515618 A5 JP 2018515618A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- nuc
- leukemia
- treatment
- acute
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NHTKGYOMICWFQZ-BBOXMAMFSA-N fosgemcitabine palabenamide Chemical compound C[C@H](N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(N)=NC2=O)C(F)(F)[C@@H]1O)OC1=CC=CC=C1)C(=O)OCC1=CC=CC=C1 NHTKGYOMICWFQZ-BBOXMAMFSA-N 0.000 claims description 25
- 208000032839 leukemia Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 201000011510 cancer Diseases 0.000 claims 16
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 3
- 210000000130 stem cell Anatomy 0.000 claims 3
- 230000003442 weekly effect Effects 0.000 claims 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 208000006990 cholangiocarcinoma Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 206010004593 Bile duct cancer Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 201000001342 Fallopian tube cancer Diseases 0.000 claims 1
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 201000004462 Leydig Cell Tumor Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 1
- 206010038111 Recurrent cancer Diseases 0.000 claims 1
- 206010070308 Refractory cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000026900 bile duct neoplasm Diseases 0.000 claims 1
- 201000009036 biliary tract cancer Diseases 0.000 claims 1
- 208000020790 biliary tract neoplasm Diseases 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000002740 oral squamous cell carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 9
- 229960005277 gemcitabine Drugs 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 206010000830 Acute leukaemia Diseases 0.000 description 5
- 208000036676 acute undifferentiated leukemia Diseases 0.000 description 5
- 231100000433 cytotoxic Toxicity 0.000 description 5
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/GB2015/051438 WO2016181093A1 (en) | 2015-05-14 | 2015-05-14 | Cancer treatments |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019040537A Division JP6810763B2 (ja) | 2019-03-06 | 2019-03-06 | がん治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018515618A JP2018515618A (ja) | 2018-06-14 |
| JP2018515618A5 true JP2018515618A5 (enExample) | 2018-07-26 |
| JP6761852B2 JP6761852B2 (ja) | 2020-09-30 |
Family
ID=53276184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018511527A Expired - Fee Related JP6761852B2 (ja) | 2015-05-14 | 2015-05-14 | がん治療 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20180289733A1 (enExample) |
| EP (2) | EP3415149A1 (enExample) |
| JP (1) | JP6761852B2 (enExample) |
| KR (1) | KR20180021697A (enExample) |
| CN (2) | CN115837028A (enExample) |
| AU (2) | AU2015394135B2 (enExample) |
| BR (1) | BR112017024461B1 (enExample) |
| CA (1) | CA2985540C (enExample) |
| CY (1) | CY1120516T1 (enExample) |
| DK (1) | DK3197456T3 (enExample) |
| EA (1) | EA201792509A1 (enExample) |
| ES (1) | ES2668377T3 (enExample) |
| HR (1) | HRP20180762T1 (enExample) |
| HU (1) | HUE038541T2 (enExample) |
| IL (1) | IL255591B (enExample) |
| LT (1) | LT3197456T (enExample) |
| MX (2) | MX374946B (enExample) |
| MY (1) | MY192081A (enExample) |
| PH (1) | PH12017502086B1 (enExample) |
| PL (1) | PL3197456T3 (enExample) |
| PT (1) | PT3197456T (enExample) |
| RS (1) | RS57371B1 (enExample) |
| SI (1) | SI3197456T1 (enExample) |
| SM (1) | SMT201800303T1 (enExample) |
| TR (1) | TR201806642T4 (enExample) |
| WO (1) | WO2016181093A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| DK3447061T3 (da) | 2011-03-01 | 2022-01-03 | NuCana plc | Farmaceutisk formulering omfattende et phosphoramidatderivat af 5-fluor-2'-deoxyuridin til anvendelse i cancerbehandling |
| HUE044605T2 (hu) | 2012-11-16 | 2019-11-28 | Univ College Cardiff Consultants Ltd | RP/SP gemcitabin-[fenil-(benziloxi-L-alaninil)]-foszfát keveréke |
| KR102563040B1 (ko) | 2014-06-25 | 2023-08-02 | 뉴카나 피엘씨 | 젬시타빈 전구 약물 |
| PT3119794T (pt) | 2014-06-25 | 2018-01-15 | Nucana Biomed Ltd | Formulação que compreende um pró-fármaco de gemcitabina |
| GB201417644D0 (en) | 2014-10-06 | 2014-11-19 | Nucana Biomed Ltd | Method of separating phosphate diastereoisomers |
| CN111909231B (zh) | 2014-11-28 | 2025-10-17 | 努卡那有限公司 | 作为抗癌化合物的新的2’和/或5’-氨基酸酯氨基磷酸酯3’-脱氧腺苷衍生物 |
| EP3353201B1 (en) | 2015-09-25 | 2021-09-08 | F. Hoffmann-La Roche AG | Recombinant immunoglobulin heavy chains comprising a sortase conjugation loop and conjugates thereof |
| CA2994502C (en) | 2015-10-05 | 2023-08-01 | NuCana plc | Combination therapy comprising nuc-1031 and carboplatin for cancer treatment |
| SMT202100665T1 (it) | 2015-12-11 | 2022-03-21 | NuCana plc | Sintesi diastereoselettiva di derivati di fosfato e del profarmaco di gemcitabina nuc-1031 |
| GB201522771D0 (en) | 2015-12-23 | 2016-02-03 | Nucana Biomed Ltd | Crystalline form of a phosphate derivative |
| WO2017109444A1 (en) * | 2015-12-23 | 2017-06-29 | Nucana Biomed Limited | Combination therapy |
| AU2016375861B2 (en) * | 2015-12-23 | 2021-12-23 | NuCana plc | Combination therapy |
| GB201609600D0 (en) * | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Cancer treatments |
| GB201709471D0 (en) | 2017-06-14 | 2017-07-26 | Nucana Biomed Ltd | Diastereoselective synthesis of hosphate derivatives |
| GB201713916D0 (en) * | 2017-08-30 | 2017-10-11 | Nucana Biomed Ltd | Treatment regimens |
| WO2020077353A2 (en) * | 2018-10-12 | 2020-04-16 | The Regents Of The University Of Colorado, A Body Corporate | Compositions and methods for reducing cancer stem cells |
| CN117462555B (zh) * | 2021-01-31 | 2025-12-30 | 兰州大学 | 6-巯基鸟嘌呤在制备预防和/或治疗酒精性胃溃疡药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0317009D0 (en) * | 2003-07-21 | 2003-08-27 | Univ Cardiff | Chemical compounds |
| CN104586832B (zh) * | 2007-09-10 | 2018-02-16 | 北京强新生物科技有限公司 | 用于癌症治疗的组合物和方法 |
| EP2274617A4 (en) * | 2008-04-10 | 2011-11-09 | Massachusetts Inst Technology | METHOD OF DETECTING AND USING MEDIUM-TREATMENT AID ON CANCER STEM CELLS |
-
2015
- 2015-05-14 KR KR1020177035629A patent/KR20180021697A/ko not_active Ceased
- 2015-05-14 CN CN202310013004.2A patent/CN115837028A/zh not_active Withdrawn
- 2015-05-14 MX MX2017014544A patent/MX374946B/es active IP Right Grant
- 2015-05-14 RS RS20180575A patent/RS57371B1/sr unknown
- 2015-05-14 PT PT157262585T patent/PT3197456T/pt unknown
- 2015-05-14 CA CA2985540A patent/CA2985540C/en active Active
- 2015-05-14 US US15/573,969 patent/US20180289733A1/en not_active Abandoned
- 2015-05-14 HU HUE15726258A patent/HUE038541T2/hu unknown
- 2015-05-14 EA EA201792509A patent/EA201792509A1/ru unknown
- 2015-05-14 TR TR2018/06642T patent/TR201806642T4/tr unknown
- 2015-05-14 PH PH1/2017/502086A patent/PH12017502086B1/en unknown
- 2015-05-14 SM SM20180303T patent/SMT201800303T1/it unknown
- 2015-05-14 MY MYPI2017001657A patent/MY192081A/en unknown
- 2015-05-14 DK DK15726258.5T patent/DK3197456T3/en active
- 2015-05-14 JP JP2018511527A patent/JP6761852B2/ja not_active Expired - Fee Related
- 2015-05-14 MX MX2020009154A patent/MX390506B/es unknown
- 2015-05-14 HR HRP20180762TT patent/HRP20180762T1/hr unknown
- 2015-05-14 AU AU2015394135A patent/AU2015394135B2/en not_active Ceased
- 2015-05-14 EP EP18164408.9A patent/EP3415149A1/en not_active Withdrawn
- 2015-05-14 SI SI201530240T patent/SI3197456T1/en unknown
- 2015-05-14 CN CN201580081668.6A patent/CN107835687A/zh active Pending
- 2015-05-14 WO PCT/GB2015/051438 patent/WO2016181093A1/en not_active Ceased
- 2015-05-14 LT LTEP15726258.5T patent/LT3197456T/lt unknown
- 2015-05-14 ES ES15726258.5T patent/ES2668377T3/es active Active
- 2015-05-14 PL PL15726258T patent/PL3197456T3/pl unknown
- 2015-05-14 EP EP15726258.5A patent/EP3197456B2/en active Active
- 2015-05-14 BR BR112017024461-6A patent/BR112017024461B1/pt not_active IP Right Cessation
-
2017
- 2017-11-12 IL IL255591A patent/IL255591B/en unknown
-
2018
- 2018-05-18 CY CY20181100519T patent/CY1120516T1/el unknown
-
2020
- 2020-09-22 US US17/028,314 patent/US20210100825A1/en not_active Abandoned
-
2021
- 2021-11-30 AU AU2021277614A patent/AU2021277614A1/en not_active Abandoned
-
2022
- 2022-08-08 US US17/883,472 patent/US20230226092A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Beatty et al. | The biological underpinnings of therapeutic resistance in pancreatic cancer | |
| Wu et al. | First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study | |
| Thielen et al. | Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch–Belgian Cooperative Trial for Haemato-Oncology (HOVON) | |
| HRP20180762T1 (hr) | Liječenje karcinoma | |
| JP2019521971A5 (enExample) | ||
| Kim et al. | Non-thermal plasma induces AKT degradation through turn-on the MUL1 E3 ligase in head and neck cancer | |
| SA520411982B1 (ar) | Kirsten 2 مثبطات نظير الجين الورمي الفيروسي لساركوما جرذ (KRas) واستخدامها لعلاج السرطان | |
| MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
| Thamrongwaranggoon et al. | Targeting hexokinase II as a possible therapy for cholangiocarcinoma | |
| Zhu et al. | Neferine promotes the apoptosis of HNSCC through the accumulation of p62/SQSTM1 caused by autophagic flux inhibition | |
| CY1123501T1 (el) | Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος | |
| PH12021550965A1 (en) | Combination therapy for treatment of hematological diseases | |
| MX395613B (es) | COMPOSICIONES DE ZINC-y-PGA Y MÉTODOS PARA TRATAR EL CANCER. | |
| WO2015158890A3 (en) | Pancreatic cancer therapy and diagnosis | |
| CY1120906T1 (el) | Συνθεσεις οξπρενολολης για τη θεραπεια του καρκινου | |
| Lee et al. | Metastatic potential in MDA-MB-231 human breast cancer cells is inhibited by proton beam irradiation via the Akt/nuclear factor-κB signaling pathway | |
| EP4552696A3 (en) | Methods for predicting drug responsiveness in cancer patients | |
| MX2018001965A (es) | Formulaciones liquidas que contienen picosulfato y citrato de magnesio. | |
| You et al. | KML001 induces apoptosis and autophagic cell death in prostate cancer cells via oxidative stress pathway | |
| MX2018003697A (es) | Metodos para el tratamiento de linfoma difuso de linfocitos b grandes y uso de biomarcadores como predictores de receptividad a farmacos. | |
| PH12016502403A1 (en) | Compositions for anti-inflammatory, antioxidant effects and improved respiratory function by specific histone deacetylase inhibition | |
| Tuttle et al. | Soluble guanylate cyclase stimulators increase sensitivity to cisplatin in head and neck squamous cell carcinoma cells | |
| EA202193276A1 (ru) | Способы лечения холангиокарциномы | |
| BR112021016923A2 (pt) | Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits | |
| Ramakrishna et al. | Modulation of CD22 antigen density improves efficacy of CD22 chimeric antigen receptor (CAR) T cells against CD22lo B-lineage leukemia and lymphoma |